Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.3.1.9: enoyl-[acyl-carrier-protein] reductase (NADH)

This is an abbreviated version!
For detailed information about enoyl-[acyl-carrier-protein] reductase (NADH), go to the full flat file.

Word Map on EC 1.3.1.9

Reaction

an acyl-[acyl-carrier protein]
+
NAD+
=
a trans-2,3-dehydroacyl-[acyl-carrier protein]
+
NADH
+
H+

Synonyms

2-trans enoyl-ACP-reductase, 2-trans enoyl-acyl carrier protein reductase, 2-trans-enoyl-ACP (CoA) reductase, 2-trans-enoyl-ACP reductase, 2-trans-enoyl-ACP(CoA) reductase, ACP reductase, BaENR, BMA0885, bsFabI, cold-shock induced protein 15, CSI15, EACP reductase, enoyl (acyl carrier protein) reductase, enoyl ACP reductase, enoyl acyl carrier protein reductase, enoyl acyl carrier protein reductase InhA, enoyl reductase, enoyl-ACP reductase, enoyl-ACP reductase I, enoyl-ACP reductase III, enoyl-ACP(CoA) reductase, enoyl-acyl carrier protein, enoyl-acyl carrier protein reductase, enoyl-acyl carrier protein reductase I, enoyl-reductase, enoyl-[acyl-carrier-protein] reductase, ENR, ENR1, ENR2, FabI, FabI-1, FabI-related enoyl-ACP reductase, FabI1, FabI2, FabK, Fabl1, Fabl2, FabMG, FabV, FAS-II enoyl reductase, FTT_0782, InhA, More, MtENR, MtInhA, NAD-dependent enoyl-ACP reductase, NADH-dependent enoyl reductase, NADH-dependent enoyl-ACP reductase, NADH-dependent enoyl-acyl carrier protein reductase, NADH-enoyl acyl carrier protein reductase, NADH-ENR, NADH-specific enoyl-ACP reductase, OsmC, PA2950, pfENR, reductase, enoyl-[acyl carrier protein], trans-enoyl-[acyl carrier protein] reductase, trans-enoyl-[acyl-carrier-protein] reductase, VEG241, vegetative protein 241, VF_0888, YP_4011

ECTree

     1 Oxidoreductases
         1.3 Acting on the CH-CH group of donors
             1.3.1 With NAD+ or NADP+ as acceptor
                1.3.1.9 enoyl-[acyl-carrier-protein] reductase (NADH)

Inhibitors

Inhibitors on EC 1.3.1.9 - enoyl-[acyl-carrier-protein] reductase (NADH)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-catechin gallate
-
IC50: 0.3 microM
(-)-epicatechin gallate
-
IC50: 0.2 microM
(-)-epigallocatechin gallate
-
IC 50: 0.2 microM
(-)-gallocatechin gallate
-
IC50: 0.5 microM
(1H-indol-5-yl)[4-[(4-methylphenyl)(phenyl)methyl]piperazin-1-yl]methanone
0.015 mM, 74% inhibition
(2E)-1-[4-(1H-pyrrol-1-yl)phenyl]-3-[4-(trifluoromethyl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(1,2,3,4,5,6-hexahydropyrido[2,3-b][1,5]diazocin-8-yl)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide
(2E)-3-(4-methoxyphenyl)-1-[4-(1H-pyrrol-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(4-methylphenyl)-1-[4-(1H-pyrrol-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-(6-aminopyridin-3-yl)-N-(4-methoxyphenyl)prop-2-enamide
-
(2E)-3-(6-aminopyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]prop-2-enamide
(2E)-3-(6-fluorocyclohexa-1,5-dien-1-yl)-1-[4-(1H-pyrrol-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-pyren-1-yl-1-[4-(1H-triaziren-1-yl)phenyl]prop-2-en-1-one
-
45% residual activity at 0.05 mM
(2E)-3-[(4Z)-4-ethylidenecyclohexa-1,5-dien-1-yl]-1-[4-(1H-pyrrol-1-yl)phenyl]prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-2-cyano-N-(6-methylpyridin-2-yl)prop-2-enamide
-
-
(2E)-3-[6-(acetylamino)pyridin-3-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]prop-2-enamide
-
(2E)-N-(1H-indol-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide
-
-
(2E)-N-(2-aminobenzyl)-3-(6-aminopyridin-3-yl)prop-2-enamide
-
(2E)-N-(3-methoxy-2-propoxybenzyl)-N-methyl-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-(3-methoxy-2-propoxybenzyl)-N-methyl-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(4-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-b][1,5]diazocin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-[3-(2-morpholin-4-ylethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)methyl]-N-methyl-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)methyl]-N-methyl-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E,4E)-N-[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]hexa-2,4-dienamide
-
(2E,4E)-N-[4-(2,4-dichlorophenoxy)-3-hydroxyphenyl]hexa-2,4-dienamide
-
(2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate
-
-
(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate
-
-
(3aR,4S,6aR)-3,3a,4,6a-tetrahydro-2H-cyclopenta[b]furan-4,5-diyldimethanol
-
-
(4-(9H-fluoren-9-yl) piperazin-1-yl)-(4-methylbenzyl)-methanone
0.015 mM, 99% inhibition
(4-(9H-fluoren-9-yl)piperazin-1-yl) (2,5-difluorophenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (2-fluorophenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (3-fluorophenyl)methanone
uncompetitive versus NADH, competitive versus trans-2-dodecenoyl-CoA
(4-(9H-Fluoren-9-yl)piperazin-1-yl) (3-tolyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (4-chlorophenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (4-fluorophenyl)methanone
uncompetitive versus NADH, competitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (4-methoxyphenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (4-tolyl)methanone
uncompetitive versus NADH, competitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (phenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-(1H-indole-5-carbonyl)-methanone
0.015 mM, 84% inhibition
(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-(4-methylbenzyl)-methanone
0.015 mM, 83% inhibition
(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-benzyl-methanone
0.015 mM, 81% inhibition
(4-methylphenyl)[4-[(4-methylphenyl)(phenyl)methyl]piperazin-1-yl]methanone
0.015 mM, 77% inhibition
(4S)-1-(2,4-dimethylphenyl)-4-(3-{4-[(propan-2-yl)oxy]phenyl}-1,2,4-oxadiazol-5-yl)pyrrolidin-2-one
-
-
(4S)-1-(3,4-dimethylphenyl)-4-(3-{4-[(propan-2-yl)oxy]phenyl}-1,2,4-oxadiazol-5-yl)pyrrolidin-2-one
-
-
(5Z)-3-(3-chlorophenyl)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(3-chlorophenyl)-5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(3-fluorophenyl)-5-(furan-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-fluorophenyl)-5-[(3-hydroxyphenyl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-methoxyphenyl)-5-(phenylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-methoxyphenyl)-5-[(4-methoxyphenyl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-methoxyphenyl)-5-[[4-(1-methylethyl)phenyl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-[3-chloro-4-(2-methylprop-1-en-1-yl)phenyl]-5-[(5,6-dihydroxy-1,6-dihydropyridazin-3-yl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-[4-(diethylamino)phenyl]-5-[(4-methoxyphenyl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(anthracen-9-ylmethylidene)-3-(4-methoxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(2,4-dichlorophenyl)methylidene]-3-(4-hydroxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-3-phenyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(3,5-dichloro-4-hydroxyphenyl)methylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(3-hydroxy-5-methoxyphenyl)methylidene]-3-(4-hydroxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(3-hydroxyphenyl)methylidene]-3-phenyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(4-hydroxy-3-methoxyphenyl)methylidene]-3-(4-hydroxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(4-methoxynaphthalen-1-yl)methylidene]-3-(4-methoxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(5,6-dihydroxy-1,6-dihydropyridazin-3-yl)methylidene]-2-thioxo-3-(3,4,5-trimethylcyclohex-1-en-1-yl)-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(5,6-dihydroxy-1,6-dihydropyridazin-3-yl)methylidene]-3-(7-ethenyl-2,3-dihydro-1H-inden-5-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[4-(diethylamino)-2-hydroxyphenyl]methylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-3-(4-hydroxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-3-(4-methoxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(2,3-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(2,5-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(2-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3,5-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(E)-1-benzyl-2-methyl-3-[2-(pyridin-3-yl)vinyl]-4-pyridone
-
IC50: higher than 0.100 mM
(E)-2-(2-ionicotinoylhydrazineylidene)-N-(3,4,5-trichlorophenyl)propanamide
-
(E)-2-(2-isonicotinoylhydrazineylidene)-N-[3-(trifluoromethoxy)phenyl]propanamide
-
(E)-2-(2-isonicotinoylhydrazineylidene)-N-[3-(trifluoromethyl)phenyl]propanamide
-
(E)-2-(2-isonicotinoylhydrazineylidene)-N-[4-(perfluorooctyl)phenyl]propanamide
-
(E)-2-(2-isonicotinoylhydrazineylidene)-N-[4-(trifluoromethoxy)phenyl]propanamide
-
(E)-2-(2-isonicotinoylhydrazineylidene)-N-[4-(trifluoromethyl)phenyl]propanamide
-
(E)-2-(2-isonicotinoylhydrazineylidene)-N-{4-[(trifluoromethyl)thio]phenyl}propanamide
-
(E)-2-(2-isonicotinoylhydrazineylidene)propanoic acid
-
(E)-N-(1,2-dimethyl-1-H-indol-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetra hydro-1,8-naphthyridin-3-yl)acrylamide
-
(E)-N-(3,4-dichlorophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(3,4-difluorophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(3,5-dichlorophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(3-bromophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(3-chlorophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(3-fluorophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(3-iodophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(4-bromophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(4-chlorophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(4-fluorophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-(4-iodophenyl)-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-N-(1,2,7-trimethyl-1H-indol-3-ylmethyl)acrylamide
-
0.00007 mM, 50% inhibition
(E)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphtyridin-3-yl)-N-(1,2,7-trimethyl-1H-indol-3-ylmethyl)acrylamide
-
0.00002 mM, 50% inhibition
(E)-N-methyl-N-(1,2-dimethyl-1H-indol-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
(E)-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
(E)-N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
(E)-N-methyl-N-(2-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
(E)-N-[3,5-bis(trifluoromethyl)phenyl]-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(E)-N-[4-(difluoromethoxy)phenyl]-2-(2-isonicotinoylhydrazineylidene)propanamide
-
(RS)-1-hydroxy-1-[3-(octadecyloxy)-phenyl]-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one
-
28% inhibition at 0.03 mM, IC50 for growth of Mycobacterium tuberculosis is 0.012 mM
(RS)-1-[3-(dodecylsulfanyl)phenyl]-1-hydroxy-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one
-
15% inhibition at 0.03 mM, IC50 for growth of Mycobacterium tuberculosis is 0.0065 mM
1,3-bis(2,6-dichlorobenzyl)-2-methyl-4-pyridone
1,3-dibenzyl-2-methyl-4-pyridone
1-(2,4-dichlorobenzyl)-5,6-dimethyl-1H-benzimidazole
-
1-(2,4-dichlorophenyl)-3-(3-methylpyridin-2-yl)thiourea
47% inhibition at 0.05 mM
-
1-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)-1,2-diazepane-3,7-dione
18% inhibition at 0.05 mM
-
1-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)-1,2-dihydropyridazine-3,6-dione
less than 5% inhibition at 0.05 mM
-
1-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)-4-methyl-1,2-dihydropyridazine-3,6-dione
42% inhibition at 0.05 mM
-
1-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)-4-methylenetetrahydropyridazine-3,6-dione
50% inhibition at 0.05 mM
-
1-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)tetrahydropyridazine-3,6-dione
32% inhibition at 0.05 mM
-
1-(2-bromobenzyl)-3-(4-nitrophenyl)thiourea
78% inhibition at 0.05 mM
-
1-(2-bromobenzyl)-3-phenylthiourea
23% inhibition at 0.05 mM
-
1-(2-chlorobenzyl)-3-(4-nitrophenyl)thiourea
72% inhibition at 0.05 mM
-
1-(2-chlorobenzyl)-3-phenylthiourea
31% inhibition at 0.05 mM
-
1-(2-chlorobenzyl)-3-phenylurea
14% inhibition at 0.05 mM
-
1-(2-chlorobenzyl)-4-(naphthalen-1-ylmethoxy)pyridin-2(1H)-one
-
-
1-(2-chlorobenzyl)-4-(naphthalen-2-ylmethoxy)pyridin-2(1H)-one
-
-
1-(2-chlorobenzyl)-4-hexylpyridin-2(1H)-one
competitive
1-(2-chlorobenzyl)-4-[(4-methoxybenzyl)oxy]pyridin-2(1H)-one
-
1-(2-chlorobenzyl)-4-[3-(1H-imidazol-1-yl)propoxy]pyridin-2(1H)-one
-
-
1-(2-chlorobenzyl)-4-[3-(1H-indol-1-yl)propoxy]pyridin-2(1H)-one
-
-
1-(3,4-dichlorobenzyl)-5,6-dimethyl-1H-benzimidazole
compound has significant antibacterial activity against both Gram-positive and Gram-negative bacterial pathogens
1-(3,5-bis(trifluoromethyl)phenyl)-3-(3-methylpyridin-2-yl)thiourea
22% inhibition at 0.05 mM
-
1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-ylethoxy)pyridin-2(1H)-one
1-(3-amino-2-methylbenzyl)-4-hexylpyridin-2(1H)-one
competitive
1-(3-chloro-4-nitrophenyl)-1,3-dihydro-2H-benzimidazol-2-one
-
1-(3-chlorobenzyl)-3-(2,6-dichlorobenzyl)-2-methylpyridin-4(1H)-one
1-(3-chlorocyclohexyl)-4-[(2-fluorophenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(3,4-dichlorophenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(3,4-dimethylphenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(3-chlorophenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(3-methylphenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(4-fluorophenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(4-methylphenyl)carbonyl]piperazine
-
1-(3-methylpyridin-2-yl)-3-(2-(trifluoromethyl)phenyl)thiourea
32% inhibition at 0.05 mM
-
1-(3-methylpyridin-2-yl)-3-(4-tolyl)thiourea
23% inhibition at 0.05 mM
-
1-(3-methylpyridin-2-yl)-3-(naphthalen-2-yl)thiourea
38% inhibition at 0.05 mM
-
1-(3-methylpyridin-2-yl)-3-phenylthiourea
35% inhibition at 0.05 mM
1-(4-(1H-pyrrol-1-yl)benzoyl)-1,2-diazepane-3,7-dione
27% inhibition at 0.05 mM
-
1-(4-(2,5-dimethyl-1H-pyrrol-1-yl)benzoyl)-1,2-diazepane-3,7-dione
13% inhibition at 0.05 mM
-
1-(4-amino-2-chlorobenzyl)-4-(benzyloxy)pyridin-2(1H)-one
-
-
1-(4-aminobenzyl)-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
1-(4-bromophenyl)-3-(3-methylpyridin-2-yl)thiourea
25% inhibition at 0.05 mM
-
1-(4-bromophenyl)-3-(dibenzo[b,d]furan-3-ylamino)propan-1-one
-
47% residual activity at 0.05 mM
1-(4-chlorobenzyl)-5,6-dimethyl-1H-benzimidazole
-
1-(4-fluorophenyl)-3-(3-methylpyridin-2-yl)thiourea
17% inhibition at 0.05 mM
-
1-(4-iodophenyl)-3-(3-methylpyridin-2-yl)thiourea
8% inhibition at 0.05 mM
-
1-(4-methoxyphenyl)-3-(3-methylpyridin-2-yl)thiourea
20% inhibition at 0.05 mM
-
1-(4-methyl-1,3-thiazol-2-yl)-1-(5-[[6-(morpholin-4-yl)pyridin-2-yl]amino]-1,3,4-thiadiazol-2-yl)ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-(5-[[6-(piperidin-1-yl)pyridin-2-yl]amino]-1,3,4-thiadiazol-2-yl)ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-(5-[[6-(trifluoromethyl)pyridin-2-yl]amino]-1,3,4-thiadiazol-2-yl)ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-[5-[(1-methyl-1H-1,2,3-triazol-4-yl)amino]-1,3,4-thiadiazol-2-yl]ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-[5-[(pyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-[5-[(pyrimidin-2-yl)amino]-1,3,4-thiadiazol-2-yl]ethan-1-ol
-
-
1-(4-nitrobenzoyl)-1,3-dihydro-2H-benzimidazol-2-one
-
1-(4-nitrobenzyl)-1,3-dihydro-2H-benzimidazol-2-one
-
1-(5-[[5-bromo-6-(trifluoromethyl)pyridin-2-yl]amino]-1,3,4-thiadiazol-2-yl)-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-(9H-fluoren-9-yl)-4-(phenylcarbonyl)piperazine
-
1-(9H-fluoren-9-yl)-4-[(4-methylphenyl)carbonyl]piperazine
-
1-(cyclohexylmethyl)-3-(2,6-dichlorobenzyl)-2-methylpyridin-4(1H)-one
-
-
1-(cyclohexylmethyl)-4-(phenylcarbonyl)piperazine
-
1-([1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]methyl)-4-methylpiperazine
i.e. BM-212
-
1-benzyl-2-butyl-3-(2,6-dichlorobenzyl)-4-pyridone
1-benzyl-2-methyl-3-(2,4,6-trichlorobenzyl)-4-pyridone
1-benzyl-2-methyl-3-phenyl-4-pyridone
-
IC50: 0.0029 mM
1-benzyl-2-methyl-3-vinyl-4-pyridone
-
IC50: higher than 0.100 mM
1-benzyl-2-methyl-3-[2-(pyridin-3-yl)ethyl]-4-pyridone
-
IC50: higher than 0.100 mM
1-benzyl-3-(2,4-dichlorobenzyl)-2-methyl-4-pyridone
1-benzyl-3-(2,6-dichlorobenzyl)-2-ethyl-4-pyridone
1-benzyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
1-benzyl-3-(2,6-difluorobenzyl)-2-methyl-4-pyridone
1-benzyl-3-(2,6-dimethylbenzyl)-2-methyl-4-pyridone
1-benzyl-3-(2-chloro-6-fluorobenzyl)-2-methyl-4-pyridone
1-benzyl-3-(2-chlorobenzyl)-2-methyl-4-pyridone
1-benzyl-3-butyl-2-methyl-4-pyridone
1-benzyl-4-(benzyloxy)pyridin-2(1H)-one
-
-
1-benzyl-4-decylpyridin-2(1H)-one
-
1-benzyl-4-hydroxypyridin-2(1H)-one
-
less than 30% inhibition at 0.1 mM
1-benzyl-4-[3-(9H-carbazol-9-yl)propoxy]pyridin-2(1H)-one
-
less than 30% inhibition at 0.1 mM
1-bicyclo[2.2.1]hept-2-yl-N-biphenyl-3-yl-5-oxopyrrolidine-3-carboxamide
-
1-butyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
1-butyl-5-(2,4-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-butyl-5-(2,4-dimethylphenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-butyl-5-(4-chloro-2-methylphenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-cycloheptyl-N-(2'-hydroxy-1,1':3',1''-terphenyl-4'-yl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-4-(2,3-dihydro-1H-indol-1-ylcarbonyl)pyrrolidin-2-one
-
1-cyclohexyl-4-(phenylcarbonyl)piperazine
-
1-cyclohexyl-4-([4-[(4-fluorophenyl)(phenyl)methyl]piperazin-1-yl]carbonyl)pyrrolidin-2-one
-
1-cyclohexyl-4-([4-[(4-methylphenyl)(phenyl)methyl]piperazin-1-yl]carbonyl)pyrrolidin-2-one
-
1-cyclohexyl-4-[(3,4-dichlorophenyl)carbonyl]piperazine
-
1-cyclohexyl-4-[(4-methylphenyl)carbonyl]piperazine
-
1-cyclohexyl-5-oxo-N-phenylpyrrolidine-3-carboxamide
-
1-cyclohexyl-5-oxo-N-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(2'-hydroxy-1,1':3',1''-terphenyl-5'-yl)-5-oxopyrrolidine-3-carboxamide
-
-
1-cyclohexyl-N-(2,4-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(2,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(2,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(2-methyl-4-nitrophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3,5-difluorophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3,5-diphenyl-4-hydroxyl)phenyl-5-oxopyrrolidine-3-carboxamide
best inhibitor of the sreening with an IC50: 62 nanoM
1-cyclohexyl-N-(3-methylphenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3-nitrophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(4-iodophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(9-ethyl-9H-carbazol-2-yl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-9H-fluoren-4-yl-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-[(2'-hydroxy-1,1':3',1''-terphenyl-5'-yl)methyl]-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-[3-(1-methylethyl)phenyl]-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-[3-methoxy-5-(trifluoromethyl)phenyl]-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexylmethyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
1-cyclooctyl-N-(2'-hydroxy-1,1':3',1''-terphenyl-4'-yl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclopropyl-5-(2,3-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-cyclopropyl-5-(2,4-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-cyclopropyl-5-(2,4-dimethylphenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-cyclopropyl-5-(2,6-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-decyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
1-ethoxy-1-oxopropan-2-yl 5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrobenzoate
-
1-hydroxy-2,3,1-benzodiazaborinine-2(1H)-carbothioamide
-
1-[(2-chlorophenyl)methyl]-4-decylpyridin-2(1H)-one
-
1-[(2H-1,3-benzodioxol-5-yl)methyl]-5,6,7,8-tetrahydro-1H-naphtho[2,3-d]imidazole
-
1-[(3,4-dichlorophenyl)methyl]-5,6-dimethyl-1H-benzimidazole
-
1-[(3,4-dimethoxyphenyl)methyl]-5,6,7,8-tetrahydro-1H-naphtho[2,3-d]imidazole
-
1-[(3,4-dimethylphenyl)carbonyl]-4-[3-(trifluoromethyl)cyclohexyl]piperazine
-
1-[(3-amino-2-methylphenyl)methyl]-4-decylpyridin-2(1H)-one
-
1-[(3-chlorophenyl)carbonyl]-4-(cyclohexylmethyl)piperidine
-
1-[(3-methylphenyl)carbonyl]-4-(4-nitrocyclohexyl)piperazine
-
1-[(4-methoxy-3-methylphenyl)methyl]-1,5,6,7-tetrahydroindeno[5,6-d]imidazole
-
1-[(4-methoxy-3-methylphenyl)methyl]-5,6,7,8-tetrahydro-1H-naphtho[2,3-d]imidazole
-
1-[(4-methylphenyl)carbonyl]-4-[3-(trifluoromethyl)cyclohexyl]piperazine
-
1-[(4-nitrophenyl)sulfonyl]-1,3-dihydro-2H-benzimidazol-2-one
-
1-[1-(3,4-dichlorophenyl)ethyl]-1,5,6,7-tetrahydroindeno[5,6-d]imidazole
-
1-[1-(3,4-dichlorophenyl)ethyl]-5,6,7,8-tetrahydro-1H-naphtho[2,3-d]imidazole
-
1-[1-(3,4-dichlorophenyl)ethyl]-5,6-dimethyl-1H-benzimidazole
-
1-[1-(3,4-dichlorophenyl)ethyl]-5,7-dihydro-1H-furo[3,4-f]benzimidazole
-
1-[1-(3,4-dichlorophenyl)ethyl]-6,6-dimethyl-1,5,6,7-tetrahydroindeno[5,6-d]imidazole
-
1-[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]-2-phenylethane-1,2-dione
-
-
1-[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]propane-1,2-dione
-
-
1-[4-(2,4-dichlorophenoxy)-3-hydroxyphenyl]-2-phenylethan-1-one
-
-
1-[4-(2,4-dichlorophenoxy)-3-hydroxyphenyl]propan-1-one
-
-
1-[4-(2-hydroxy-4-propylphenoxy)phenyl]ethanone
A0A348A0U3
-
1-[4-[4-(4-chloro-2-hydroxyphenoxy)phenyl]piperazin-1-yl]ethan-1-one
-
25% inhibition 0.001 mM
1-[5-(3-bromo-4-fluoroanilino)-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-(4-chloro-2-hydroxyphenoxy)thiophen-2-yl]propan-1-one
-
75% inhibition 0.001 mM
1-[5-[(1-methyl-1H-pyrazol-3-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(1-methyl-1H-pyrazol-4-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(2-methoxypyridin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(2-methylpyridin-3-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(5-bromo-6-methylpyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(5-bromopyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(5-fluoropyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(5-methylpyridin-3-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-bromopyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-cyclopropylpyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-fluoropyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-methoxypyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-methylpyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-methylpyridin-3-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[9-[4-(1H-indol-5-ylcarbonyl)piperazin-1-yl]-9H-fluoren-1-yl]ethanone
-
1-[bis(4-fluorophenyl)methyl]-4-(phenylcarbonyl)piperazine
-
1-[bis(4-fluorophenyl)methyl]-4-[(4-methylphenyl)carbonyl]piperazine
-
2,13-dioxapentacyclo[18.2.2.23,6.29,12.214,17]triaconta-1(22),3,5,9,11,14,16,20,23,25,27,29-dodecaene-4,11-diol
52% inhibition at 0.05 mM
-
2,13-dioxapentacyclo[18.2.2.23,6.29,12.214,17]triaconta-1(22),3,5,9,11,14,16,20,23,25,27,29-dodecaene-4,15-diol
93% inhibition at 0.05 mM
-
2,4,4'-trichloro-2'-hydroxydiphenyl ether
trivial name triclosan
2,4-dichloro-N-(2-[[2-oxo-2-(phenylamino)ethyl]sulfanyl]-1,3-benzothiazol-6-yl)benzamide
-
49% residual activity at 0.05 mM
2-(2'-amino-4'-chloro-phenoxy)-5-chloro-phenol
-
inhibits the parasite growth, uncompetitive inhibition kinetics with crotonoyl-CoA and competitive with NADH
2-(2,4-dichlorophenoxy)-5-(2-ethylbutyl)phenol
-
-
2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol
2-(2,4-dichlorophenoxy)-5-(2-methylpropyl)phenol
2-(2,4-dichlorophenoxy)-5-(2-phenylethyl)phenol
2-(2,4-dichlorophenoxy)-5-(2H-tetrazol-5-yl)phenol
-
-
2-(2,4-dichlorophenoxy)-5-(3-methylbutyl)phenol
2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol
2-(2,4-dichlorophenoxy)-5-(4-phenylbutyl)phenol
2-(2,4-dichlorophenoxy)-5-(hexylamino)phenol
-
73% inhibition at 1 mM
2-(2,4-dichlorophenoxy)-5-(pyridin-2-ylmethyl)phenol
-
-
2-(2,4-dichlorophenoxy)-5-(pyridin-3-ylmethyl)phenol
-
-
2-(2,4-dichlorophenoxy)-5-chlorophenol
triclosan, dissociation constant of the inhibitor from the enzyme-NAD+ product complex: 7.0 pM
2-(2,4-dichlorophenoxy)-5-ethylphenol
2-(2,4-dichlorophenoxy)-5-methylphenol
2-(2,4-dichlorophenoxy)-5-propylphenol
2-(2,4-dichlorophenoxy)-5-pyridin-3-ylphenol
-
-
2-(2,4-dichlorophenoxy)-5-[(1H-1,2,3-triazol-1-yl)methyl]phenol
-
97% inhibition at 1 mM
2-(2,4-dichlorophenoxy)-5-[(2-methylphenyl)methyl]phenol
2-(2,4-dichlorophenoxy)-5-[(3-methylphenyl)methyl]phenol
2-(2,4-dichlorophenoxy)-5-[(4-fluorophenyl)methyl]phenol
2-(2,4-dichlorophenoxy)-5-[(pyridin-2-yl)methyl]phenol
2-(2,4-dichlorophenoxy)-5-[(pyridin-3-yl)methyl]phenol
2-(2,4-dichlorophenoxy)-5-[5-(trimethylsilyl)-1,2-oxazol-3-yl]phenol
-
complete inhibition at 1 mM
2-(2,4-dinitrophenoxy)-5-propylphenol
2-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)-2,3-dihydrophthalazine-1,4-dione
63% inhibition at 0.05 mM
-
2-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)-5,6,7,8-tetrabromo-2,3-dihydrophthalazine-1,4-dione
11% inhibition at 0.05 mM
-
2-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)-5,6,7,8-tetrachloro-2,3-dihydrophthalazine-1,4-dione
12% inhibition at 0.05 mM
-
2-(2-(4-(1H-pyrrol-1-yl)phenoxy)acetyl)octahydrophthalazine-1,4-dione
less than 5% inhibition at 0.05 mM
-
2-(2-amino-4-chlorophenoxy)-5-chlorophenol
IC50 for Plasmodium falciparum in culture 0.0084 mM
2-(2-aminophenoxy)-5-chlorophenol
-
-
2-(2-aminophenoxy)-5-decylphenol
-
2-(2-chloro-4-fluorophenyl)-N-(4-((3,5-dimethyl-1H-pyrazol-1-yl)-methyl)phenyl)acetamide
-
2-(2-chloro-4-nitrophenoxy)-5-propylphenol
2-(2-chlorophenoxy)-5-decylphenol
-
2-(2-hydroxybenzyl)-phenol
-
uncompetitive inhibition
2-(2-hydroxyphenoxy)phenol
-
2-(2-hydroxyphenyl)-phenol
-
uncompetitive inhibition
2-(2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(5-nitrothiazol-2-yl)acetamide
-
2-(2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide
-
2-(2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(thiophen-2-ylmethyl)acetamide
-
2-(2-methyl-4-oxoquinazolin-3(4H)-yl)-N-phenylacetamide
-
2-(2-[(benzylamino)methyl]-4-chlorophenoxy)-5-chlorophenol
-
-
2-(3-chlorophenoxy)-5-propylphenol
-
2-(3-dimethylaminophenoxy)-5-propylphenol
A0A348A0U3
-
2-(3-hydroxy-5-methylphenoxy)-5-methoxy-3-methyl phenol
-
cyperin
2-(3-hydroxymethyl-phenoxy)-5-propylphenol
A0A348A0U3
-
2-(3-nitrophenoxy)-5-propylphenol
2-(4-(1H-pyrrol-1-yl)benzoyl)-5,6,7,8-tetrabromo-2,3-dihydrophthalazine-1,4-dione
72% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)benzoyl)-5,6,7,8-tetrachloro-2,3-dihydrophthalazine-1,4-dione
64% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(1-(4-bromophenyl)ethylidene)acetohydrazide
27% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(1-(4-chlorophenyl)ethylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(1-(4-hydroxyphenyl)ethylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(1-(4-nitrophenyl)ethylidene)acetohydrazide
51% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(1-phenylethylidene)acetohydrazide
34% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(2,3-dichlorobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(2,4-dichlorobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(2,4-dimethoxybenzylidene)acetohydrazide
37% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(2,6-dichlorobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(2-chlorobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(2-nitrobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(3,4-dichlorobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(3-bromobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(3-ethoxy-4-hydroxybenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(3-hydroxybenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(3-methoxybenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(3-phenoxybenzylidene)acetohydrazide
15% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(4-chlorobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(4-fluorobenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(4-hydroxy-3-methoxybenzylideneacetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(4-hydroxybenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(4-isopropylbenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(4-methoxybenzylidene)acetohydrazide
21% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-(4-methylbenzylidene)acetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N'-benzylideneacetohydrazide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(1,3-dioxoisoindolin-2-yl)acetamide
25% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(1,3-dioxooctahydro-2H-isoindol-2-yl)acetamide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(2,5-dioxo-2,5-dihydro-1Hpyrrol-1-yl)acetamide
10% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(2,5-dioxopyrrolidin-1-yl)acetamide
less than 5% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(2,6-dioxopiperidin-1-yl)acetamide
20% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(3-methyl-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)acetamide
10% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(3-methylene-2,5-dioxopyrrolidin-1-yl)acetamide
21% inhibition at 0.05 mM
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(4,5,6,7-tetrabromo-1,3-dioxoisoindolin-2-yl)acetamide
-
-
2-(4-(1H-pyrrol-1-yl)phenoxy)-N-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)acetamide
-
-
2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)benzoyl)-5,6,7,8-tetrabromo-2,3-dihydrophthalazine-1,4-dione
75% inhibition at 0.05 mM
-
2-(4-(2,5-dimethyl-1H-pyrrol-1-yl)benzoyl)-5,6,7,8-tetrachloro-2,3-dihydrophthalazine-1,4-dione
76% inhibition at 0.05 mM
-
2-(4-amino-2-chlorophenoxy)-5-chlorophenol
-
-
2-(4-aminophenoxy)-5-chlorophenol
A0A348A0U3
-
2-(4-aminophenoxy)-5-decylphenol
-
2-(4-aminophenoxy)-5-propylphenol
2-(4-chlorophenoxy)-5-(1H-1,2,3-triazol-1-yl)phenol
-
-
2-(4-chlorophenoxy)-5-cyclohexylphenol
-
-
2-(4-chlorophenoxy)-5-hexylphenol
-
-
2-(4-chlorophenoxy)-5-[4-(1H-1,2,3-triazol-1-yl)butyl]phenol
-
-
2-(4-methanesulfinylphenoxy)-5-propylphenol
A0A348A0U3
-
2-(4-methanesulfonylphenoxy)-5-propylphenol
A0A348A0U3
-
2-(4-methylsulfanylphenoxy)-5-propylphenol
A0A348A0U3
-
2-(4-nitrophenoxy)-5-propylphenol
2-(4-oxoquinazolin-3(4H)-yl)-N-(thiophen-2-ylmethyl)acetamide
-
2-(4-oxoquinazolin-3(4H)-yl)-N-phenylacetamide
-
2-(4-[[(2,3-dihydro-1-benzofuran-6-ylmethyl)amino]methyl]-2-hydroxyphenoxy)-5-methylbenzonitrile
-
predicted inhibitor, based on in-silico screening
2-(5-chlorothiophen-2-yl)-N-[2-(1,2,3,4-tetrahydronaphthalen-1-yl)ethyl]quinoline-4-carboxamide
-
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(2-chloro-5-(trifluoromethyl)phenyl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(5-nitrothiazol-2-yl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(furan-2-ylmethyl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(thiophen-2-ylmethyl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-phenylacetamide
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-[(furan-2-yl)methyl]acetamide
78.12% inhibition at 0.01 mM
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(2-chloro-5-(trifluoromethyl)phenyl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(5-nitrothiazol-2-yl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(furan-2-ylmethyl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(thiophen-2-ylmethyl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-phenylacetamide
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-[2-chloro-5-(trifluoromethyl)phenyl]acetamide
80.12% inhibition at 0.01 mM
-
2-(biphenyl-3-yloxy)-5-propylphenol
A0A348A0U3
-
2-(biphenyl-4-yloxy)-5-chlorophenol
2-(dimethylamino)ethyl 3-[(5Z)-5-[(2,4-dichlorophenyl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoate
-
-
2-(dimethylamino)ethyl 6-[(5Z)-4-oxo-5-(phenylmethylidene)-2-thioxo-1,3-thiazolidin-3-yl]hexanoate
-
-
2-(ethanesulfonyl)-6-[2-[(E)-(hydroxyimino)methyl]-4-(trifluoromethyl)phenoxy]-2,3,1-benzodiazaborinin-1(2H)-ol
-
2-(ethanesulfonyl)-7-[2-[(Z)-(hydroxyimino)methyl]-4-(trifluoromethyl)phenoxy]-2,3,1-benzodiazaborinin-1(2H)-ol
diazaborine, in vitro bactericidal activity against replicating bacteria active against several drug-resistant clinical isolates. AN12855 binds to and inhibits the substrate-binding site of InhA in a cofactor-independent manner. It shows good drug exposure after i.v. and oral delivery, with 53% oral bioavailability. Delivered orally, AN12855 exhibits dose-dependent efficacy in both an acute and chronic murine model of tuberculosis infection. AN12855 is a promising candidate for the development of new antitubercular agents
2-(o-tolyloxy)-5-hexylphenol
2-(toluene-4-sulfonyl)-2H-benzo[d][1,2,3]diazaborinin-1-ol
-
2-amino-N-(5-chloro-2-phenoxyphenyl)pyridine-3-carboxamide
-
2-decyl-1-methyl-5-(2-methylphenoxy)pyridin-4(1H)-one
-
2-decyl-1-methyl-5-(4-nitrophenoxy)pyridin-4(1H)-one
competitive inhibition
2-methylsulfonyl-6-methylbenzodiazaborine
-
2-methylsulfonyl-benzodiazaborine
-
2-phenoxy-5-propylphenol
2-phenoxy-5-tetradecylphenol
-
2-phenoxyphenol
2-[(2-fluorophenyl)methyl]-N-[(1S)-1-(2-methyl-1,3-thiazol-4-yl)ethyl]-1,3-benzoxazole-5-carboxamide
-
-
2-[(3-chlorophenyl)sulfanyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)quinoline-4-carboxamide
-
-
2-[(6-ethoxy-1,3-benzothiazol-2-yl)sulfanyl]-N-(4-methylphenyl)acetamide
-
25% residual activity at 0.05 mM
2-[(E)-[(4-phenyl-1,3-thiazol-2-yl)imino]methyl]phenol
-
-
2-[(E)-[(5-methyl-4-phenyl-1,3-thiazol-2-yl)imino]methyl]phenol
-
-
2-[2-(dimethylamino)-4-sulfanylphenoxy]-5-[[(2-phenylethyl)amino]methyl]phenol
-
predicted inhibitor, based on in-silico screening
2-[2-(dimethylamino)-4-sulfanylphenoxy]-5-{[(2-phenylethyl)amino]methyl}phenol
2-[2-[(benzylamino)methyl]phenoxy]-5-chlorophenol
-
-
2-[2-[4-(1H-pyrrol-1-yl)benzoyl]hydrazineylidene]-N-(4-fluorophenyl)propanamide
-
2-[3-(2-hydroxy-4-chlorophenoxy)phenoxy]-5-chlorophenol
A0A348A0U3
-
2-[3-(2-hydroxy-4-propylphenoxy)phenoxy]-5-propylphenol
A0A348A0U3
-
2-[3-(2-hydroxy-ethyl)phenoxy]-5-propylphenol
A0A348A0U3
-
2-[3-(2-hydroxyethyl)phenoxy]-5-propylphenol
-
2-[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]-2-oxoacetamide
-
-
2-[4-(1-hydroxyethyl)phenoxy]-5-propylphenol
A0A348A0U3
-
2-[4-(2,4-dinitrophenyl)-1H-pyrazol-1-yl]-4-(trifluoromethyl)pyrimidine
-
-
2-[4-(2-hydroxy-4-chlorophenoxy)phenoxy]-5-chlorophenol
A0A348A0U3
-
2-[4-(2-hydroxy-4-propylphenoxy)phenoxy]-5-propylphenol
A0A348A0U3
-
2-[4-(benzylamino)-2-chlorophenoxy]-5-chlorophenol
-
-
2-[4-({[(2,3-dihydro-1-benzofuran-6-yl)methyl]amino}methyl)-2-hydroxyphenoxy]-5-methylbenzonitrile
2-[amino(hydroxy)methyl]-2,3,1-benzodiazaborinin-1(2H)-ol
-
2-[[4-amino-5-(3,4-dichlorophenyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-N-naphthalen-2-ylacetamide
-
3% residual activity at 0.05 mM
2-[[4-amino-5-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-N-[4-bromo-2-(1-methylethyl)phenyl]acetamide
-
52% residual activity at 0.05 mM
2-[[6-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]-N-(4-fluorophenyl)acetamide
-
20% residual activity at 0.05 mM
2-{4-[(4-benzyl-1H-1,2,3-triazol-1-yl)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
2-{4-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
2-{4-[(5-benzyl-1,2-oxazol-3-yl)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
2-{4-[(5-butyl-1,2-oxazol-3-yl)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
2-{4-[(benzylamino)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
3'-methyl-4-[2-(methylamino)-4-(3-methylbutyl)phenoxy][1,1'-biphenyl]-3-ol
3'-methyl-4-[2-(methylamino)-4-(propan-2-yl)phenoxy][1,1'-biphenyl]-3-ol
3'-methyl-4-{[3-(methylamino)[1,1'-biphenyl]-4-yl]oxy}[1,1'-biphenyl]-3-ol
3,7-dihydroxy-flavone
-
IC50: 10 microM
3-(2,4-dichlorophenoxy)-6-methoxypyridin-2(1H)-one
-
-
3-(2,6-dichlorobenzyl)-1,2-dimethyl-4-pyridone
3-(2,6-dichlorobenzyl)-1-(4-nitrobenzyl)-2-methyl-4-pyridone
3-(2,6-dichlorobenzyl)-1-(5-hydroxypentyl)-2-methyl-4-pyridone
3-(2,6-dichlorobenzyl)-1-furfuryl-2-methyl-4-pyridone
3-(2,6-dichlorobenzyl)-2-methyl-1-(2-methyl-2-[[3-(trifluoromethyl)benzyl]sulfanyl]propyl)pyridin-4(1H)-one
-
-
3-(2,6-dichlorobenzyl)-2-methyl-1-(thiophen-2-ylmethyl)pyridin-4(1H)-one
3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
3-(2-(4-methylbenzylidene)hydrazinyl)-N-(2-(trifluoromethyl)phenyl)-1,2,4-thiadiazol-5-amine
-
64% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
3-(2-(4-methylbenzylidene)hydrazinyl)-N-(4-nitrophenyl)-1,2,4-thiadiazol-5-amine
-
8% inhibition at 0.05 mM
-
3-(2-(4-methylbenzylidene)hydrazinyl)-N-(p-tolyl)-1,2,4-thiadiazol-5-amine
-
21% inhibition at 0.05 mM
-
3-(2-(4-methylbenzylidene)hydrazinyl)-N-phenyl-1,2,4-thiadiazol-5-amine
-
34% inhibition at 0.05 mM
-
3-(2-benzylidenehydrazinyl)-N-(2,4-dichlorophenyl)-1,2,4-thiadiazol-5-amine
-
38% inhibition at 0.05 mM
-
3-(2-benzylidenehydrazinyl)-N-(2-(trifluoromethyl)phenyl)-1,2,4-thiadiazol-5-amine
-
50% inhibition at 0.05 mM
-
3-(2-benzylidenehydrazinyl)-N-(4-bromophenyl)-1,2,4-thiadiazol-5-amine
-
61% inhibition at 0.05 mM, 39% inhibition at 0.005 mM
-
3-(2-benzylidenehydrazinyl)-N-(4-fluorophenyl)-1,2,4-thiadiazol-5-amine
-
54% inhibition at 0.05 mM
-
3-(2-benzylidenehydrazinyl)-N-(4-iodophenyl)-1,2,4-thiadiazol-5-amine
-
-
-
3-(2-benzylidenehydrazinyl)-N-(4-methoxyphenyl)-1,2,4-thiadiazol-5-amine
-
46% inhibition at 0.05 mM
-
3-(2-benzylidenehydrazinyl)-N-(4-nitrophenyl)-1,2,4-thiadiazol-5-amine
-
35% inhibition at 0.05 mM
-
3-(2-benzylidenehydrazinyl)-N-(p-tolyl)-1,2,4-thiadiazol-5-amine
-
75% inhibition at 0.05 mM, 48% inhibition at 0.005 mM
-
3-(2-benzylidenehydrazinyl)-N-phenyl-1,2,4-thiadiazol-5-amine
-
16% inhibition at 0.05 mM
-
3-(2-chlorophenoxy)-6-methoxypyridin-2(1H)-one
-
-
3-(2-hydroxy-4-propylphenoxy)benzoic acid
A0A348A0U3
-
3-(2-hydroxy-4-propylphenoxy)benzoic acid methylester
A0A348A0U3
-
3-(3-hydroxy-4-phenoxyphenyl)propane-1,2-diol
A0A348A0U3
-
3-(4-(4-chloro-2-hydroxyphenoxy)phenyl)-7-hydroxy-2H-chromen-2-one
-
3-(4-chloro-2-hydroxyphenoxy)-4-methyl-2H-chromen-2-one
-
3-(4-chloro-2-hydroxyphenoxy)-5,7-dihydroxy-2H-chromen-2-one
-
3-(4-chloro-2-hydroxyphenoxy)-6-hydroxy-2H-chromen-2-one
-
3-(4-chloro-2-hydroxyphenoxy)-7-hydroxy-2H-chromen-2-one
-
3-(4-chloro-2-hydroxyphenoxy)-7-hydroxy-4-methyl-2H-chromen-2-one
-
3-(4-methoxyphenyl)-N-(6-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)propanamide
-
-
3-benzyl-6-(benzyloxy)pyridin-2(1H)-one
-
-
3-bromo-N-(4-fluorobenzyl)-1-benzothiophene-2-carboxamide
-
competitive kinetics with cofactor NADH and uncompetitive kinetics with the substrate crotonyl-CoA
3-bromo-N-[4-(trifluoromethyl)benzyl]-1-benzothiophene-2-carboxamide
-
competitive kinetics with cofactor NADH and uncompetitive kinetics with the substrate crotonyl-CoA
3-chloro-4-(2,6-dihydroxy-4-propylphenoxy)benzoic acid
-
3-chloro-4-(2-hydroxy-4-propylphenoxy)benzamide
A0A348A0U3
-
3-chloro-4-(2-hydroxy-4-propylphenoxy)benzonitrile
3-chloro-4-(2-hydroxy-4-pyridin-2-ylphenoxy)benzonitrile
-
-
3-chloro-4-(2-hydroxy-4-pyridin-4-ylphenoxy)benzonitrile
-
-
3-chloro-4-(2-hydroxy-6-methoxy-4-propylphenoxy)benzonitrile
-
3-chloro-4-(4-chloro-2-hydroxyphenoxy)-N-hydroxybenzamide
-
-
3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzaldehyde
-
-
3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide
-
-
3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzoic acid
-
-
3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzonitrile
-
-
3-chloro-4-[(3-hydroxy-2'-methylbiphenyl-4-yl)oxy]benzonitrile
-
-
3-chloro-4-[2-hydroxy-4-(pyridin-4-ylmethyl)phenoxy]benzonitrile
-
-
3-chloro-4-[2-hydroxy-4-[(2-methylphenyl)methyl]phenoxy]benzonitrile
3-chloro-4-[2-hydroxy-4-[(pyridin-4-yl)methyl]phenoxy]benzonitrile
3-cyclohexylmethyl-1-benzyl-2-methyl-4-pyridone
3-formyl-2-phenoxy phenol
3-hydroxy-4-phenoxy benzoic acid
3-hydroxy-4-phenoxy benzyl alcohol
3-hydroxy-4-phenoxybenzaldehyde
IC50 for Plasmodium falciparum in culture 0.077 mM
3-[(2E)-2-benzylidenehydrazinyl]-N-(2,4-dichlorophenyl)-1,2,4-thiadiazol-5-amine
-
-
3-[(2E)-2-benzylidenehydrazinyl]-N-(4-bromophenyl)-1,2,4-thiadiazol-5-amine
-
-
3-[(2E)-2-benzylidenehydrazinyl]-N-(4-methoxyphenyl)-1,2,4-thiadiazol-5-amine
-
-
3-[(2E)-2-[(4-methylphenyl)methylidene]hydrazinyl]-N-phenyl-1,2,4-thiadiazol-5-amine
-
-
3-[(4-methylcyclohexyl)sulfamoyl]-N-(4-methylphenyl)benzamide
-
49% residual activity at 0.05 mM
3-[2-(3-fluoro-4-methoxyphenyl)-2-oxoethoxy]-6H-benzo[c]chromen-6-one
-
9% residual activity at 0.05 mM
3-[2-(4-bromophenyl)-2-oxoethoxy]-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
-
53% residual activity at 0.05 mM
3-[3-(2-hydroxy-4-propylphenoxy)phenyl]acrylic acid methylester
A0A348A0U3
-
3-[3-(2-hydroxy-4-propylphenoxy)phenyl]propionic acid
A0A348A0U3
-
3-[3-(2-hydroxy-4-propylphenoxy)phenyl]propionic acid methylester
A0A348A0U3
-
3-[5-chloro-2-(2,4-dichlorophenoxy)phenoxy]pyridine
A0A348A0U3
-
3-[5-[(Z)-[4-oxo-2-thioxo-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid
-
-
4,4'-dichloro-2-hydroxydiphenyl ether
diclosan
4-(2',4'-dichlorophenoxy)-3-hydroxybenzaldehyde
4-(2',4'-dichlorophenoxy)-3-hydroxybenzoic acid
4-(2',4'-dichlorophenoxy)-3-hydroxybenzyl alcohol
4-(2',4'-dichlorophenoxy)-3-hydroxybenzylchloride
4-(2',4'-dinitrophenoxy)-3-hydroxybenzaldehyde
4-(2',4'-dinitrophenoxy)-3-hydroxybenzoic acid
4-(2,4-dichlorophenoxy)-2'-methylbiphenyl-3-ol
-
-
4-(2,4-dichlorophenoxy)-3'-methylbiphenyl-3-ol
-
-
4-(2,4-dichlorophenoxy)-3-hydroxybenzaldehyde
IC50 for Plasmodium falciparum in culture 0.021 mM
4-(2,4-dichlorophenoxy)-3-hydroxybenzamide
-
-
4-(2,4-dichlorophenoxy)-3-hydroxybenzoic acid
-
-
4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile
4-(2,4-dichlorophenoxy)-4'-fluorobiphenyl-3-ol
-
-
4-(2,4-dichlorophenoxy)-4'-methylbiphenyl-3-ol
-
-
4-(2,4-dichlorophenoxy)-N-hexyl-3-hydroxybenzamide
-
-
4-(2,4-dichlorophenoxy)biphenyl-3-ol
-
-
4-(2,6-dihydroxy-4-propylphenoxy)benzamide
-
4-(2,6-dihydroxy-4-propylphenoxy)benzonitrile
-
4-(4-chloro-2-hydroxyphenoxy)-1-(4-methylphenylsulphonamido)benzene
A0A348A0U3
-
4-(4-chlorophenoxy)-3-hydroxybenzonitrile
-
-
4-(4-chlorophenoxy)[1,1'-biphenyl]-3-ol
-
-
4-(4-hydroxyphenoxy)benzene-1,3-diol
-
4-(4-hydroxyphenyl)-phenol
-
uncompetitive inhibition
4-(7-chloroquinolin-4-yl)-2-[(diethylamino)methyl]phenol
-
-
4-(benzyloxy)-1-(2-chloro-4-nitrobenzyl)pyridin-2(1H)-one
4-(benzyloxy)-1-(2-chlorobenzyl)pyridin-2(1H)-one
4-(cyclohexylmethyl)-1-[(2-fluorophenyl)carbonyl]piperidine
-
4-(cyclohexylmethyl)-1-[(3-methylphenyl)carbonyl]piperidine
-
4-(cyclohexylmethyl)-1-[(4-methylphenyl)carbonyl]piperidine
-
4-([4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]carbonyl)-1-cyclohexylpyrrolidin-2-one
-
4-([4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]carbonyl)-1-cyclohexylpyrrolidin-2-one
-
4-([[1-(2-chlorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl)benzonitrile
-
-
4-acetoxyanthecotulide
-
moderate inhibition
4-bromo-N-(4-chlorophenyl)-3-(phenylsulfamoyl)benzamide
-
46% residual activity at 0.05 mM
4-bromo-N-[2-(3,4-dimethoxyphenyl)-1,3-benzoxazol-5-yl]benzamide
-
17% residual activity at 0.05 mM
4-bromo-N-[4-(trifluoromethyl)phenyl]benzamide
-
49% residual activity at 0.05 mM
4-chloro-1-(4-chloro-2-methoxyphenoxy)-2-nitrobenzene
-
-
4-decyl-1-[(2-methylphenyl)methyl]pyridin-2(1H)-one
-
4-decyl-1-[(4-nitrophenyl)methyl]pyridin-2(1H)-one
noncompetitive inhibition
4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one
-
less than 30% inhibition at 0.1 mM
4-hydroxy-1-(4-methoxybenzyl)pyridin-2(1H)-one
-
less than 30% inhibition at 0.1 mM
4-hydroxyanthecotulide
-
moderate inhibition
4-hydroxymercuribenzoate
-
-
4-methylthiazole
-
-
4-phenoxybenzamide adenine dinucleotide
NAD analogue which mimics isoniazid-NAD adduct
4-phenoxybenzene-1,3-diol
4-[(3'-methoxy[1,1'-biphenyl]-3-yl)carbamoyl]-1-(3-methylbut-2-en-1-yl)piperidin-1-ium
-
-
4-[(3-ethyl[1,1'-biphenyl]-4-yl)oxy]-3'-methyl[1,1'-biphenyl]-3-ol
4-[(E)-[(4-phenyl-1,3-thiazol-2-yl)imino]methyl]phenol
-
-
4-[(E)-[(5-methyl-4-phenyl-1,3-thiazol-2-yl)imino]methyl]phenol
-
-
4-[(Z)-[3-(4-methoxyphenyl)-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl]benzaldehyde
-
-
4-[2-(dimethylamino)-4-(3-methylbutyl)phenoxy]-3'-methyl[1,1'-biphenyl]-3-ol
4-[2-(dimethylamino)-4-(propan-2-yl)phenoxy]-3'-methyl[1,1'-biphenyl]-3-ol
4-[2-ethyl-4-(3-methylbutyl)phenoxy]-3'-methyl[1,1'-biphenyl]-3-ol
4-[2-ethyl-4-(propan-2-yl)phenoxy]-3'-methyl[1,1'-biphenyl]-3-ol
4-[2-[(3-cyano-4,6-dithiophen-2-ylpyridin-2-yl)sulfanyl]ethyl]benzoic acid
-
-
4-[3-(1H-benzotriazol-1-yl)propoxy]-1-(2-chlorobenzyl)pyridin-2(1H)-one
-
-
4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzamide
4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzoic acid
4-[3-(9H-carbazol-9-yl)propoxy]-1-(2-chlorobenzyl)pyridin-2(1H)-one
4-[3-(9H-carbazol-9-yl)propoxy]-1-(4-methoxybenzyl)pyridin-2(1H)-one
-
-
4-[4-({[2-(4-chlorophenyl)ethyl]amino}methyl)-2-hydroxyphenoxy]-3-(methylamino)anilinium
4-[4-[(benzylamino)methyl]-2-hydroxyphenoxy]-3-chlorobenzonitrile
-
predicted inhibitor, based on in-silico screening
4-[5-chloro-2-(4-chloro-2-hydroxyphenoxy)phenyl]amino-4-oxobutanoic acid
-
-
4-[5-chloro-2-(4-chloro-2-methoxyphenoxy)phenyl]amino-4-oxobutanoic acid
-
-
4-[[1-hydroxy-2-(methanesulfonyl)-1,2-dihydro-2,3,1-benzodiazaborinin-7-yl]oxy]benzonitrile
-
4-[[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl]-3-chlorobenzamide
-
-
4-[[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl]-3-chlorobenzoic acid
-
-
4-[[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl]-3-chlorobenzonitrile
-
-
4-{4-[(benzylamino)methyl]-2-hydroxyphenoxy}-3-chlorobenzonitrile
4-{[3-(dimethylamino)[1,1'-biphenyl]-4-yl]oxy}-3'-methyl[1,1'-biphenyl]-3-ol
4-{[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl}-3-chlorobenzamide
-
4-{[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl}-3-chlorobenzoic acid
-
4-{[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl}-3-chlorobenzonitrile
-
5,11-dimethyl-8H-[2,3,1]benzodiazaborinino[2',1':5,6][1,3,5,2,6]oxadiazadiborinino[2,3-a][2,3,1]benzodiazaborinin-8-one
-
5-((4-(1H-pyrrol-1-yl)phenoxy)methyl)-1,3,4-oxadiazole-2-thiol
57% inhibition at 0.05 mM
-
5-((4-(1H-pyrrol-1-yl)phenoxy)methyl)-4-amino-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-(2,3-dichlorophenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,3-dichlorophenoxy)-2-(phenoxymethyl)-4H-pyran-4-one
-
-
5-(2,3-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,3-dichlorophenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,3-dichlorophenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,3-dichlorophenoxy)-2-[(E)-2-phenylethenyl]-4H-pyran-4-one
-
-
5-(2,4-dichlorophenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,4-dichlorophenoxy)-2-(phenoxymethyl)-1-phenylpyridin-4(1H)-one
-
-
5-(2,4-dichlorophenoxy)-2-(phenoxymethyl)-4H-pyran-4-one
-
-
5-(2,4-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,4-dichlorophenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,4-dichlorophenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,4-dichlorophenoxy)-2-[(E)-2-phenylethenyl]-4H-pyran-4-one
-
-
5-(2,4-dimethylphenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,4-dimethylphenoxy)-2-(phenoxymethyl)-1-phenylpyridin-4(1H)-one
-
-
5-(2,4-dimethylphenoxy)-2-(phenoxymethyl)-4H-pyran-4-one
-
-
5-(2,4-dimethylphenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,4-dimethylphenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,4-dimethylphenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,4-dimethylphenoxy)-2-[(E)-2-phenylethenyl]-4H-pyran-4-one
-
-
5-(2,6-dichlorophenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,6-dichlorophenoxy)-2-(phenoxymethyl)-4H-pyran-4-one
-
-
5-(2,6-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,6-dichlorophenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,6-dichlorophenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,6-dichlorophenoxy)-2-[(E)-2-phenylethenyl]-4H-pyran-4-one
-
-
5-(2-chloro-3-nitrophenoxy)-1-cyclopropyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2-chloro-3-nitrophenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2-chloro-3-nitrophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2-chlorophenoxy)-2-methoxypyridine 1-oxide
-
less than 30% inhibition at 0.1 mM
5-(2-methyl-3-nitrophenoxy)-2-(phenoxymethyl)-4H-pyran-4-one
-
-
5-(4-amino-2-methylphenoxy)-2-decyl-1-methylpyridin-4(1H)-one
-
5-(4-aminophenoxy)-2-decyl-1-methylpyridin-4(1H)-one
-
5-(4-chloro-2-hydroxyphenoxy)-N-(5-methyl-1,2-oxazol-3-yl)furan-2-carboxamide
-
90% inhibition 0.001 mM
5-(4-chloro-2-hydroxyphenoxy)-N-methylfuran-2-carboxamide
-
46% inhibition 0.001 mM
5-(4-chloro-2-hydroxyphenoxy)-N-[4-(prop-1-en-2-yl)piperazin-1-yl]furan-2-carboxamide
-
45% inhibition 0.001 mM
5-(4-chloro-2-hydroxyphenoxy)furan-2-carboxylic acid
-
79% inhibition 0.001 mM
5-(4-chloro-2-hydroxyphenoxy)thiophene-2-carboxylic acid
-
48% inhibition 0.001 mM
5-(4-chloro-2-methylphenoxy)-1-cyclopropyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(4-chloro-2-methylphenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(4-chloro-2-methylphenoxy)-2-(phenoxymethyl)-1-phenylpyridin-4(1H)-one
-
-
5-(4-chloro-2-methylphenoxy)-2-(phenoxymethyl)-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(1E)-3-methylbut-1-en-1-yl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(1E)-pent-1-en-1-yl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(1H-pyrrol-2-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(furan-2-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(thiophen-2-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(thiophen-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-phenylethenyl]-4H-pyran-4-one
-
-
5-(4-chlorophenoxy)-2-(methoxymethyl)-4H-pyran-4-one
-
-
5-(5-benzyl-1,2-oxazol-3-yl)-2-(2,4-dichlorophenoxy)phenol
-
-
5-(5-butyl-1,2-oxazol-3-yl)-2-(2,4-dichlorophenoxy)phenol
-
-
5-(anilinomethyl)-2-[(3-ethyl[1,1'-biphenyl]-4-yl)oxy]phenol
5-(anilinomethyl)-2-[2-(dimethylamino)-4-(3-methylbutyl)phenoxy]phenol
5-(anilinomethyl)-2-[2-(dimethylamino)-4-(propan-2-yl)phenoxy]phenol
5-(anilinomethyl)-2-[2-(methylamino)-4-(3-methylbutyl)phenoxy]phenol
5-(anilinomethyl)-2-[2-(methylamino)-4-(propan-2-yl)phenoxy]phenol
5-(anilinomethyl)-2-[2-ethyl-4-(3-methylbutyl)phenoxy]phenol
5-(anilinomethyl)-2-[2-ethyl-4-(propan-2-yl)phenoxy]phenol
5-(anilinomethyl)-2-{[3-(dimethylamino)[1,1'-biphenyl]-4-yl]oxy}phenol
5-(anilinomethyl)-2-{[3-(methylamino)[1,1'-biphenyl]-4-yl]oxy}phenol
5-(benzylamino)-2-(2,4-dichlorophenoxy)phenol
-
25% inhibition at 1 mM
5-(benzylaminomethyl)-2-phenoxyphenol
A0A348A0U3
-
5-(cyclohexylamino)-2-(2,4-dichlorophenoxy)phenol
-
12.5% inhibition at 1 mM
5-(cyclohexylmethyl)-2-(2,4-dichlorophenoxy)phenol
5-(cyclohexylmethyl)-2-[(3-ethyl[1,1'-biphenyl]-4-yl)oxy]phenol
5-(cyclohexylmethyl)-2-[2-(dimethylamino)-4-(3-methylbutyl)phenoxy]phenol
5-(cyclohexylmethyl)-2-[2-(dimethylamino)-4-(propan-2-yl)phenoxy]phenol
5-(cyclohexylmethyl)-2-[2-(methylamino)-4-(3-methylbutyl)phenoxy]phenol
5-(cyclohexylmethyl)-2-[2-(methylamino)-4-(propan-2-yl)phenoxy]phenol
5-(cyclohexylmethyl)-2-[2-ethyl-4-(3-methylbutyl)phenoxy]phenol
5-(cyclohexylmethyl)-2-[2-ethyl-4-(propan-2-yl)phenoxy]phenol
5-(cyclohexylmethyl)-2-{[3-(dimethylamino)[1,1'-biphenyl]-4-yl]oxy}phenol
5-(cyclohexylmethyl)-2-{[3-(methylamino)[1,1'-biphenyl]-4-yl]oxy}phenol
5-([4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]carbonyl)-1H-indole
-
5-([[2-(4-chlorophenyl)ethyl]amino]methyl)-2-[2-(dimethylamino)-4-ethylphenoxy]phenol
-
predicted inhibitor, based on in-silico screening
5-([[2-(4-chlorophenyl)ethyl]amino]methyl)-2-[2-ethyl-4-(sulfanylmethyl)phenoxy]phenol
-
predicted inhibitor, based on in-silico screening
5-({[(2,3-dihydro-1-benzofuran-6-yl)methyl]amino}methyl)-2-[2-methyl-4-(methylamino)phenoxy]phenol
5-({[2-(4-chlorophenyl)ethyl]amino}methyl)-2-[2-(dimethylamino)-4-ethylphenoxy]phenol
5-({[2-(4-chlorophenyl)ethyl]amino}methyl)-2-[2-ethyl-4-(sulfanylmethyl)phenoxy]phenol
5-benzyl-2-(2,4-dichlorophenoxy)phenol
-
-
5-benzyl-N-{[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]methyl}-1,2-oxazole-3-carboxamide
-
-
5-butyl-2-(2,4-dichlorophenoxy)phenol
5-butyl-2-phenoxyphenol
-
5-chloro-2-(2,4-dichloro-phenoxy)phenol
-
trivial name triclosan, slow, tight-binding inhibitor
5-chloro-2-(2,4-dichlorophenoxy)-phenol
-
Triclosan
5-chloro-2-(2,4-dichlorophenoxy)phenol
5-chloro-2-(2,4-dichlorophenoxy)phenyl 2,2-dimethylpropanoate
-
5-chloro-2-(2,4-dichlorophenoxy)pyridine 1-oxide
-
-
5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol
-
-
5-chloro-2-(2-chloro-4-morpholin-4-ylphenoxy)phenol
-
-
5-chloro-2-(2-chloro-4-nitrophenoxy)phenol
5-chloro-2-(2-chloro-4-piperidin-1-ylphenoxy)phenol
-
-
5-chloro-2-(2-chloro-4-pyrrolidin-1-ylphenoxy)phenol
-
-
5-chloro-2-(2-nitrophenoxy)phenol
5-chloro-2-(2-[[(2-phenylethyl)amino]methyl]phenoxy)phenol
-
-
5-chloro-2-(2-[[(4-chlorobenzyl)amino]methyl]phenoxy)phenol
-
-
5-chloro-2-(4'-chloro-2'-nitro-phenoxy)-phenol
-
inhibits the parasite growth
5-chloro-2-(4-chloro-2-methoxyphenoxy)aniline
-
-
5-chloro-2-(4-chloro-2-[1-[(4-chlorobenzyl)(methyl)amino]-1-methylethyl]phenoxy)phenol
-
-
5-chloro-2-(4-chloro-2-[1-[(4-chlorobenzyl)amino]-1-methylethyl]phenoxy)phenol
-
-
5-chloro-2-(4-chloro-2-[[(2,3-dihydro-1-benzofuran-5-ylmethyl)amino]methyl]phenoxy)phenol
-
-
5-chloro-2-(4-chloro-2-[[(4-chlorobenzyl)(methyl)amino]methyl]phenoxy)phenol
-
-
5-chloro-2-(4-hydroxyphenoxy)phenol
5-chloro-2-(4-nitrophenoxy)phenol
5-chloro-2-(pyrazin-2-yloxy)phenol
-
5-chloro-2-(pyridin-3-yloxy)phenol
-
5-chloro-2-phenoxyaniline
5-chloro-2-phenoxyphenol
5-chloro-2-phenoxyphenylmethanol
A0A348A0U3
-
5-chloro-2-[(5-[[4-(prop-1-en-2-yl)piperazin-1-yl]methyl]thiophen-2-yl)oxy]phenol
-
73% inhibition 0.001 mM
5-chloro-2-[(naphthalen-2-yl)oxy]phenol
-
91% inhibition 0.001 mM
5-chloro-2-[(quinolin-6-yl)oxy]phenol
-
87% inhibition 0.001 mM
5-chloro-2-[2-chloro-4-(1H-tetrazol-5-yl)phenoxy]phenol
-
-
5-chloro-2-[2-chloro-4-(chloromethyl)phenoxy]phenol
-
-
5-chloro-2-[2-chloro-4-(dimethylamino)phenoxy]phenol
-
-
5-chloro-2-[2-chloro-4-(hydroxymethyl)phenoxy]phenol
-
-
5-chloro-2-[2-chloro-4-(methylamino)phenoxy]phenol
-
-
5-chloro-2-[2-chloro-4-(morpholin-4-ylcarbonyl)phenoxy]phenol
-
-
5-chloro-2-[2-chloro-4-(naphthalen-1-ylsulfonyl)phenoxy]phenol
-
-
5-chloro-2-[2-chloro-4-(trifluoromethyl)phenoxy]phenol
-
95% inhibition 0.001 mM
5-chloro-2-[2-chloro-4-[(trifluoromethyl)sulfonyl]phenoxy]phenol
-
-
5-chloro-2-[2-[(naphthalen-1-ylamino)methyl]phenoxy]phenol
-
-
5-chloro-2-[2-[(naphthalen-2-ylamino)methyl]phenoxy]phenol
-
-
5-chloro-2-[4-(4-methylpiperazin-1-yl)phenoxy]phenol
-
81% inhibition 0.001 mM
5-chloro-2-[4-(morpholin-4-yl)phenoxy]phenol
-
74% inhibition 0.001 mM
5-chloro-2-[4-(piperidine-1-sulfonyl)phenoxy]phenol
-
78% inhibition 0.001 mM
5-chloro-2-[4-(pyrrolidine-1-sulfonyl)phenoxy]phenol
-
81% inhibition 0.001 mM
5-chloro-2-[4-chloro-2-(prop-1-en-2-ylamino)phenoxy]phenol
-
-
5-chloro-2-[4-chloro-2-[(4-phenylpiperazin-1-yl)methyl]phenoxy]phenol
-
-
5-chloro-2-[4-chloro-2-[(dimethylamino)methyl]phenoxy]phenol
-
-
5-chloro-2-[4-chloro-2-[(methylamino)methyl]phenoxy]phenol
-
-
5-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]phenoxy]phenol
-
32% inhibition 0.001 mM
5-chloro-2-{2-chloro-4-[(1H-1,2,3-triazol-1-yl)methyl]phenoxy}phenol
-
-
5-chloro-2-{2-chloro-4-[(hexylamino)methyl]phenoxy}phenol
-
38% inhibition at 1 mM
5-cyclohexyl-2-(2-hydrazinyl-4-propylphenoxy)phenol
5-cyclohexyl-2-[2-(methylamino)-4-propylphenoxy]phenol
-
predicted inhibitor, based on in-silico screening
5-decyl-2-(2-fluorophenoxy)phenol
-
5-decyl-2-(2-methylphenoxy)phenol
-
5-decyl-2-(2-nitrophenoxy)phenol
-
5-decyl-2-(4-nitrophenoxy)phenol
uncompetitive inhibition
5-decyl-2-phenoxyphenol
-
5-ethyl-2(2-hydroxyphenoxy)phenol
-
5-ethyl-2-phenoxyphenol
5-fluoro-2-phenoxyphenol
5-hydroxymethyl-2-phenoxyphenol
A0A348A0U3
-
5-methyl-2(2-hydroxyphenoxy)phenol
-
5-methyl-2-phenoxyphenol
-
slow binding inhibitor
5-methyl-N-[(1E)-(3-nitrophenyl)methylidene]-4-phenyl-1,3-thiazol-2-amine
-
-
5-nitro-2-phenoxyphenol
A0A348A0U3
-
5-octyl-2-phenoxyphenol
-
5-pentyl-2-phenoxyphenol
5-propyl-2(2-hydroxyphenoxy)phenol
-
5-propyl-2-(3-trifluoromethylphenoxy)phenol
A0A348A0U3
-
5-propyl-2-[4-(2H-tetrazol-5-yl)phenoxy]benzene-1,3-diol
-
5-[(4-benzyl-1H-1,2,3-triazol-1-yl)methyl]-2-(2,4-dichlorophenoxy)phenol
-
-
5-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]-2-(2,4-dichlorophenoxy)phenol
-
98% inhibition at 1 mM
5-[(benzylamino)methyl]-2-[2-(dimethylamino)-4-ethylphenoxy]phenol
5-[2-[(E)-(hydroxyimino)methyl]phenoxy]-2,1-benzoxaborol-1(3H)-ol
-
5-[3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-2-phenoxybenzamide
25% inhibition at 0.7 mM
5-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]pentanoic acid
-
IC50: 0.110 mM
5-[5-chloro-2-(4-chloro-2-hydroxyphenoxy)phenyl]amino-5-oxopentanoic acid
-
-
5-[5-chloro-2-(4-chloro-2-methoxyphenoxy)phenyl]amino-5-oxopentanoic acid
-
-
5-[[(2,3-dihydro-1-benzofuran-6-ylmethyl)amino]methyl]-2-[2-methyl-4-(methylamino)phenoxy]phenol
-
predicted inhibitor, based on in-silico screening
5-[[4-(2,4,7-trichloro-9H-fluoren-9-yl)piperazin-1-yl]carbonyl]-1H-indole
-
5-[[4-(2,7-dibromo-9H-fluoren-9-yl)piperazin-1-yl]carbonyl]-1H-indole
-
5-[[4-(2,7-diiodo-9H-fluoren-9-yl)piperazin-1-yl]carbonyl]-1H-indole
-
5-[[4-(2-methoxy-9H-fluoren-9-yl)piperazin-1-yl]carbonyl]-1H-indole
-
5-[[4-(2-nitro-9H-fluoren-9-yl)piperazin-1-yl]carbonyl]-1H-indole
-
5-[[4-(3-nitro-9H-fluoren-9-yl)piperazin-1-yl]carbonyl]-1H-indole
-
5-[[4-(4-methoxy-9H-fluoren-9-yl)piperazin-1-yl]carbonyl]-1H-indole
-
5-[[4-(9H-fluoren-9-yl)piperazin-1-yl]carbonyl]-1H-indole
6-(4-chloro-2-hydroxyphenoxy)-2H-chromen-2-one
-
6-(4-chloro-2-hydroxyphenoxy)-4-ethyl-2H-chromen-2-one
-
6-(4-chloro-2-hydroxyphenoxy)-4-methyl-2H-chromen-2-one
-
6-(4-chloro-2-hydroxyphenoxy)naphthalen-2-ol
-
6-(benzyloxy)-3-phenoxypyridin-2(1H)-one
-
-
6-([5-[1-hydroxy-1-(4-methyl-1,3-thiazol-2-yl)ethyl]-1,3,4-thiadiazol-2-yl]amino)pyridin-2-ol
-
-
6-butyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
6-cyclohexylmethyl-3-(2,6-dichlorobenzyl)-2-methyl-4-pyridone
6-methyl-2(propane-1-sulfonyl)-2H-thieno[3,2-d][1,2,3]diazaborinin-1-ol
-
6-methyl-2-(propane-1-sulfonyl)-4a,7a-dihydro-2H-thieno[3,2-d][1,2,3]diazaborinin-1-ol
6-[(5Z)-5-([4-[(4-chlorobenzyl)oxy]-3-methoxyphenyl]methylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoic acid
-
-
6-[(5Z)-5-[(3-methoxy-4-propoxyphenyl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoic acid
-
-
6-[(5Z)-5-[[3-methoxy-4-(pentyloxy)phenyl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoic acid
-
-
6-[(5Z)-5-[[4-(1-methylethyl)phenyl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoic acid
-
-
6-[(5Z)-5-[[4-(benzyloxy)-3-methylphenyl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoic acid
-
-
6-[(5Z)-5-[[4-(hexyloxy)-3-methoxyphenyl]methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoic acid
-
-
6-[4-(trifluoromethyl)phenoxy]-2,1-benzoxaborol-1(3H)-ol
-
6-[5-chloro-2-(4-chloro-2-hydroxyphenoxy)phenyl]amino-6-oxohexanoic acid
-
-
6-[5-chloro-2-(4-chloro-2-methoxyphenoxy)phenyl]amino-6-oxohexanoic acid
-
-
7-(4-chloro-2-hydroxyphenoxy)-2H-chromen-2-one
-
7-(4-chloro-2-hydroxyphenoxy)-4-ethyl-2H-chromen-2-one
-
7-(4-chloro-2-hydroxyphenoxy)-4-methyl-2H-chromen-2-one
-
7-[2-[(Z)-(hydroxyimino)methyl]-4-(trifluoromethyl)phenoxy]-2-(methanesulfonyl)-2,3,1-benzodiazaborinin-1(2H)-ol
-
9-[4-(1H-indol-5-ylcarbonyl)piperazin-1-yl]-N,N-dimethyl-9H-fluoren-2-amine
-
acetoacetyl-CoA
anthecotulide
apigenin
-
IC50: 50 microM
aquastatin A
-
a natural inhibitor from the fungus Sporothrix sp. strain FN611, prevents the growth of Staphylococcus pneumoniae with minimum inhibitory concentration of 0.064-0.128 mg/ml, overview
artesunate
-
-
benzo-diazaborine
-
-
betulinic acid
inhibitor identified by in silico screening, MIC value 0.1 mg/ml
cannabichromene
31% inhibition at 0.05 mM
-
carfilzomib
cerulenin
Chloroquine
-
-
ciprofloxacine
-
-
-
cis-cannabigerol
78% inhibition at 0.05 mM
-
CoASH
-
competitive inhibitor with crotonyl CoA as substrate
Colchicine
inhibitor identified by in silico screening, MIC value 0.1 mg/ml
crotonoyl-CoA
the addition of short-chain crotonoyl-CoA actually inhibits the oxidation of NADH by recombinant ENR in a dose-dependent manner
curcumin
i.e. (E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, an uncompetitive inhibition of FabI, shows antibacterial activity against Escherichia coli, sensitivity is decreased in FabI-overexpressing Escherichia coli
decanoyl-CoA
-
about 15% inhibition at 0.2 mM
degalactosylated aquastatin A
-
a natural inhibitor from the fungus Sporothrix sp. strain FN611
diazaborine
embelin
inhibitor identified by in silico screening, MIC value 0.1 mg/ml
epigallocatechin gallate
ethambutol
Ethionamide
ethionamide-NAD adduct
in its active form, ethionamide forms covalent adduct with NAD, which competitively inhibits the enzyme
-
ethyl 5-[[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl]isoxazole-3-carboxylate
-
less than 30% inhibition at 0.1 mM
fisetin
-
IC50: 1 microM
gallocatechin gallate
-
-
genistein
i.e. 4',5,7-trihydroxyisoflavone
Hexachlorophene
-
50% inhibition at 0.0025 mM
icariin
inhibitor identified by in silico screening, MIC value 0.1 mg/ml
imperatorin
i.e. 9-[(3-methyl-2-buten-1-yl)oxy]-7H-furo[3,2-g][1]benzopyran-7-one
indole
iodoacetamide
iodoacetate
-
-
iridoid aglycone
-
IC50: 40.6 microg/ml, isolated form the extract of Scrophularia lepidota roots
isoniazid
isorhamnetin
-
IC50: 5 microM
kaempferol
-
IC50: 20 microM
lauroyl-CoA
-
about 50% inhibition at 0.2 mM
lead compound
-
MIC (microg/mL): 64
-
luteolin
luteolin 7-O-beta-D-glucopyranoside
-
50% inhibition at 0.01mg/ml
methyl 2-[[(1-cyclohexyl-5-oxopyrrolidin-3-yl)carbonyl]amino]benzoate
-
methyl 2-[[(1H-benzimidazol-2-ylmethyl)carbamoyl]amino]-1,3-benzothiazole-6-carboxylate
AG205
methyl 4-[3-(2,6-dichlorobenzyl)-2-methyl-4-pyridon-1-yl]methylbenzoate
methyl 6-[(5Z)-5-[(3-hydroxyphenyl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoate
-
-
methyl 6-[(5Z)-5-[(4-chlorophenyl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoate
-
-
methyl 6-[(5Z)-5-[(4-ethylphenyl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]hexanoate
-
-
morin
-
IC50: 5 microM
myricetin
-
IC50: 0.4 microM
myristoyl-CoA
-
about 80% inhibition at 0.2 mM
N'-((1H-indol-3-yl)methylene)2-(4-(1H-pyrrol-1-yl)phenoxy)acetohydrazide
19% inhibition at 0.05 mM
-
N'-[(1E)-(5-bromo-2-hydroxyphenyl)methylidene]-4-(piperidin-1-ylsulfonyl)benzohydrazide
-
49% residual activity at 0.05 mM
N'-[(1Z)-(5-chloro-2-hydroxyphenyl)methylidene]-4-(piperidin-1-ylsulfonyl)benzohydrazide
-
24% residual activity at 0.05 mM
N'-[(Z)-[3-(4-methoxyphenyl)-1H-pyrazol-4-yl]methylidene]-2,8-dimethylquinoline-4-carbohydrazide
-
-
N,N-dibutyl-4-(2,4-dichlorophenoxy)-3-hydroxybenzamide
-
-
N-((4-bromo-1-ethyl-1H-pyrazol-5-yl)methyl)-4-((3,5-dimethyl-1Hpyrazol-1-yl)methyl)benzamide
-
N-(2,4-dichlorophenyl)-3-(2-(4-methylbenzylidene)hydrazinyl)-1,2,4-thiadiazol-5-amine
-
62% inhibition at 0.05 mM, 48% inhibition at 0.005 mM
-
N-(2,6-dichlorophenyl)-4-(2,5-dimethyl-1H-pyrrol-1-yl)benzamide
31% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
N-(2-aminophenyl)-4-(2,5-dimethyl-1H-pyrrol-1-yl)benzamide
12% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
N-(2-bromobenzyl)-4-[(3,5-dimethyl-1H-pyrazol-1-yl)methyl]benzamide
-
N-(2-chloro-4-fluorobenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(2-chloro-4-fluorobenzyl)-4-((4-methylthiazol-2-yl)methyl)-benzamide
-
N-(2-chloro-5-(2-phenylacetamido)benzyl)-4-((3,5-dimethyl-1Hpyrazol-1-yl)methyl)benzamide
-
N-(2-chloro-5-(3-phenylureido)benzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(2-chloro-5-(trifluoromethyl)phenyl)-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetamide
-
N-(2-chloro-5-(trifluoromethyl)phenyl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide
-
N-(2-chloro-5-aminobenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(2-chlorobenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(2-nitrobenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(2-phenoxyphenyl)-2-[2-(pyridin-2-yl)-1,3-thiazol-4-yl]acetamide
-
-
N-(2-trifluorobenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)-benzamide
-
N-(3-aminophenyl)-2-(4-nitrophenoxy)acetamide
-
N-(3-benzylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(3-bromobenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(3-bromophenyl)-1-(4-fluorophenyl)-5-oxopyrrolidine-3-carboxamide
-
N-(3-bromophenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(3-bromophenyl)-5-oxo-1-phenylpyrrolidine-3-carboxamide
-
N-(3-chloro-2-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(3-chloro-4-fluorophenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(3-chlorobenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(3-chlorophenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(3-chlorophenyl)-5-oxo-1-phenylpyrrolidine-3-carboxamide
-
N-(3-methanesulfonybenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)-methyl)benzamide
-
N-(3-propan-2-yloxybenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(4-acetylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(4-aminophenyl)-4-(2,5-dimethyl-1H-pyrrol-1-yl)benzamide
30% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
N-(4-bromo-3-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(4-bromo-3-methylphenyl)-2-[2-(thiophen-3-yl)-1,3-thiazol-4-yl]acetamide
-
-
N-(4-bromophenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(4-bromophenyl)-2-chloro-5-[(4-methylphenyl)sulfamoyl]benzamide
-
41% residual activity at 0.05 mM
N-(4-bromophenyl)-3-(2-(4-methylbenzylidene)hydrazinyl)-1,2,4-thiadiazol-5-amine
-
46% inhibition at 0.05 mM
-
N-(4-bromophenyl)-3-{(2E)-2-[(4-methylphenyl)methylidene]hydrazinyl}-1,2,4-thiadiazol-5-amine
-
-
N-(4-chloro-2-hydroxyphenyl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide
-
27% inhibition 0.001 mM
N-(4-chlorobenzyl)-2-[(4-chlorobenzyl)sulfanyl]quinazolin-4-amine
-
-
N-(4-chlorobenzyl)-N-[5-chloro-2-(4-chloro-2-hydroxyphenoxy)benzyl]acetamide
-
-
N-(4-fluoro-2-(trifluoromethyl)benzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(4-fluorobenzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(4-fluorophenyl)-3-(2-(4-methylbenzylidene)hydrazinyl)-1,2,4-thiadiazol-5-amine
-
67% inhibition at 0.05 mM, 26% inhibition at 0.005 mM
-
N-(4-iodophenyl)-3-(2-(4-methylbenzylidene)hydrazinyl)-1,2,4-thiadiazol-5-amine
-
34% inhibition at 0.05 mM
-
N-(4-methoxyphenyl)-2-(4-nitrophenoxy)acetamide
-
N-(4-methoxyphenyl)-3-(2-(4-methylbenzylidene)hydrazinyl)-1,2,4-thiadiazol-5-amine
-
50% inhibition at 0.05 mM
-
N-(4-[5-[(2-methylphenoxy)methyl]-1,2,4-oxadiazol-3-yl]phenyl)thiophene-2-carboxamide
-
-
N-(4-[[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl]-3-chlorophenyl)acetamide
-
-
N-(5-chloro-2-methoxyphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(5-chloro-2-methoxyphenyl)-2-(5-chlorothiophen-2-yl)quinoline-4-carboxamide
-
-
N-(5-chloro-2-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-(5-chloro-2-phenoxyphenyl)-2,2-dimethylpropanamide
-
N-(5-nitrothiazol-2-yl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide
-
N-(6-nitro-1,3-benzothiazol-2-yl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide
72.18% inhibition at 0.01 mM
-
N-(6-nitrobenzo[d]thiazol-2-yl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide
-
N-(anthracen-9-ylmethyl)-1-bicyclo[2.2.1]hept-2-yl-N-methyl-5-oxopyrrolidine-3-carboxamide
-
N-(anthracen-9-ylmethyl)-1-cycloheptyl-N-methyl-5-oxopyrrolidine-3-carboxamide
-
N-(anthracen-9-ylmethyl)-1-cyclohexyl-N-methyl-5-oxopyrrolidine-3-carboxamide
-
N-(anthracen-9-ylmethyl)-1-cyclooctyl-N-methyl-5-oxopyrrolidine-3-carboxamide
-
N-(benzo[d]thiazol-2-yl)-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetamide
-
N-(benzo[d]thiazol-2-yl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide
-
N-(benzo[d]thiazol-2-yl)-2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)acetamide
-
N-(benzyl)-4-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)benzamide
-
N-(furan-2-yl-methyl)-2-(4-oxoquinazolin-3(4H)-yl)acetamide
-
N-(furan-2-ylmethyl)-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetamide
-
N-benzyl-4-(2,4-dichlorophenoxy)-3-hydroxybenzamide
-
-
N-benzyl-4-(2,5-dimethyl-1H-pyrrol-1-yl)benzamide
12% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
N-biphenyl-3-yl-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-ethylmaleimide
N-phenyl-N'-[5-(4-propoxyphenyl)-1,3,4-thiadiazol-2-yl]urea
-
-
N-[(1E)-(2-chlorophenyl)methylidene]-4-phenyl-1,3-thiazol-2-amine
-
-
N-[(1E)-(2-chlorophenyl)methylidene]-5-methyl-4-phenyl-1,3-thiazol-2-amine
-
-
N-[(1E)-(3,4-dimethoxyphenyl)methylidene]-4-phenyl-1,3-thiazol-2-amine
-
-
N-[(1E)-(3,4-dimethoxyphenyl)methylidene]-5-methyl-4-phenyl-1,3-thiazol-2-amine
-
-
N-[(1E)-(3-nitrophenyl)methylidene]-4-phenyl-1,3-thiazol-2-amine
-
-
N-[(2-chloro-4-fluorophenyl)methyl]-4-[(2-methyl-1,3-thiazol-4-yl)methyl]benzamide
-
N-[(2-chloro-4-fluorophenyl)methyl]-4-[(3-methyl-1H-pyrazol-1-yl)methyl]benzamide
-
N-[(2-chloro-4-fluorophenyl)methyl]-4-[(6-methylpyridin-2-yl)-oxy]benzamide
-
N-[(2-chloro-4-fluorophenyl)methyl]-4-[(6-methylpyridin-2-yl)methyl]benzamide
-
N-[(2-chloro-4-fluorophenyl)methyl]-4-[(6-methylpyridin-2-yl)sulfanyl]benzamide
-
N-[(2-chloro-4-fluorophenyl)methyl]-4-[(dimethyl-1,3-thiazol-2-yl)methyl]benzamide
-
N-[(2-chloro-4-fluorophenyl)methyl]-4-[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]benzamide
-
N-[(4-fluorophenyl)methyl]-4-[[2-methyl-5-(2,2,2-trifluoroethyl)furan-3-yl]methyl]benzamide
-
N-[2-(4-anilinoanilino)-2-oxoethyl]-2H-1,3-benzodioxole-5-carboxamide
-
-
N-[2-(4-chloro-2-hydroxyphenoxy)phenyl]acetamide
-
N-[2-methyl-5-phenyl-3-([4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl)-1H-pyrrol-1-yl]pyridine-4-carboxamide
i.e. LL3858
-
N-[3,5-bis(trifluoromethyl)phenyl]-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-[3-bromo-5-(trifluoromethyl)phenyl]-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-[4-(4-bromophenyl)-1,3-thiazol-2-yl]-4-(1H-pyrrol-1-yl)benzamide
25% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
N-[4-(4-chloro-2-hydroxyphenoxy)phenyl]acetamide
N-[4-(4-chlorophenyl)-1,3-thiazol-2-yl]-4-(2,5-dimethyl-1Hpyrrol-1-yl)benzamide
38% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
N-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-4-(2,5-dimethyl-1H-pyrrol-1-yl)benzamide
38% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
N-[4-(4-nitrophenyl)-1,3-thiazol-2-yl]-4-(1H-pyrrol-1-yl)benzamide
30% inhibition at 0.05 mM, 35% inhibition at 0.005 mM
-
N-[4-(benzyloxy)phenyl]-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide
-
N-[5-(4-chloro-2-hydroxyphenoxy)pyridin-2-yl]acetamide
-
N-[5-chloro-2-(4-chloro-2-hydroxyphenoxy)benzyl]benzamide
-
-
N-[5-chloro-2-(4-chloro-2-hydroxyphenoxy)benzyl]benzenesulfonamide
-
-
N-[5-chloro-2-(4-chloro-2-methoxyphenoxy)phenyl]acetamide
-
-
N-[9-[4-(1H-indol-5-ylcarbonyl)piperazin-1-yl]-9H-fluoren-2-yl]benzamide
-
N-[9-[4-(1H-indol-5-ylcarbonyl)piperazin-1-yl]-9H-fluoren-2-yl]butanamide
-
N-[9-[4-(1H-indol-5-ylcarbonyl)piperazin-1-yl]-9H-fluoren-2-yl]formamide
-
N-{[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]methyl}-2-(3-methyl-1,2-oxazol-5-yl)acetamide
-
-
N-{[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]methyl}-5-methyl-1,2-oxazole-3-carboxamide
-
-
N-{[4-(2,4-dichlorophenoxy)-3-hydroxyphenyl]methyl}-5-methyl-1,2-oxazole-3-carboxamide
-
more than 80% inhibition at 1 mM
N1-phenylbenzene-1,2,4-triamine
-
Na3[Fe(CN)5(isonicotinic acid hydrazide)]4H2O
-
time dependent inactivation, rate constant value 327/min
NB2001
-
Triclosan prodrug form
p-chloromercuribenzoate
palmitic acid
-
-
palmitoyl-CoA
panosialin A
panosialin B
panosialin wA
panosialin wB
pentacyano (isoniazid)ferrate-II
-
[FeII(CN)5(INH)]3+, slow onset inhibitor
pentacyano(isoniazid)ferrate(II)
pentacyano(isoniazid)ferrateII complex
-
Na3[FeII(CN)5(INH)]*3H2O complex
-
Phenylglyoxal
polydatin
i.e. 3,4',5-trihydroxystilbene-3-beta-D-glucopyranoside
pyrrolidine carboxamide
IC50: 10.05 microM, chosen as a lead structure for further structure optimization
quercetin
-
IC50: 1.5 microM
rifampicin
sodium (4-[2-[([[5-(pyridin-2-ylsulfanyl)-1,3-thiazol-2-yl]carbamoyl]amino)methyl]-1H-imidazol-4-yl]phenoxy)acetate
competitive inhibitor with respect to NADH and uncompetitive inhibitor with respect to crotonyl-CoA
stearoyl-CoA
-
about 40% inhibition at 0.2 mM
tert-butyl 4-[5-(4-chloro-2-hydroxyphenoxy)thiophene-2-carbonyl]piperazine-1-carboxylate
-
76% inhibition 0.001 mM
thienodiazaborine
-
-
thiolactomycin
-
-
triclosan
Trp-Tyr-Trp
structure-based computer modelling approach to design a tripeptide inhibitor. Docking studies indicate that the designed peptide has potency 100 times higher than the best known inhibitor. The results suggest that the designed inhibitor is a suitable lead compound for the development of novel anti-TB drugs
ursolic acid
inhibitor identified by in silico screening, MIC value 0.1 mg/ml
WYW
tripeptide inhibitor, identified using a structure-based approach
[3-(2-hydroxy-4-propylphenoxy)phenyl]boronic acid
-
[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]acetonitrile
-
-
[4-(2,4-dichlorophenoxy)-3-hydroxyphenyl](morpholin-4-yl)methanone
-
-
[4-(9H-fluoren-9-yl) piperazin-1-yl]-benzyl-methanone
0.015 mM, 97% inhibition
[4-(9H-fluoren-9-yl)piperazin-1-yl](1H-indol-5-yl)methanone
0.015 mM, 94% inhibition
[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]acetonitrile
-
less than 30% inhibition at 0.1 mM
[4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl](1H-indol-5-yl)methanone
0.015 mM, 67% inhibition
[4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl](4-methylphenyl)methanone
0.015 mM, 74% inhibition
[4-[(4-fluorophenyl)(phenyl)methyl]piperazin-1-yl](1H-indol-5-yl)methanone
0.015 mM, 81% inhibition
[4-[(4-fluorophenyl)(phenyl)methyl]piperazin-1-yl](phenyl)methanone
0.015 mM, 81% inhibition
[4-[4-([[2-(4-chlorophenyl)ethyl]amino]methyl)-2-hydroxyphenoxy]-3-(methylamino)phenyl]methanaminium
-
predicted inhibitor, based on in-silico screening
[5-(3-carbamoyl-4-phenoxyphenyl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl dihydrogen phosphate
12% inhibition at 0.1 mM
[5-(4-chloro-2-hydroxyphenoxy)thiophen-2-yl](piperazin-1-yl)methanone
-
60% inhibition 0.001 mM
[5-chloro-2-(2,4-dichlorophenoxy)phenol]
[9-[4-(1H-indol-5-ylcarbonyl)piperazin-1-yl]-9H-fluoren-2-yl]carbamic acid
-
[oxydi(2,3,1-benzodiazaborinine-1,2-diyl)]bis[(pyridin-4-yl)methanone]
-
additional information
-